Crew Named CEO at Lannett
26 December 2017 - - US-based generic pharmaceutical company Lannett Company, Inc.'s (NYSE: LCI) board of directors has named Timothy C. Crew as the company's chief executive officer, effective 2 January 2018, the company said.

Lannett said its board of directors intends to appoint Crew as a director of the company after completion of its 2018 annual meeting of Stockholders. Crew will succeed Arthur Bedrosian, who will continue to serve as CEO until Crew joins the company.

Crew has more than 25 years of experience in the generic and branded pharmaceutical industries, most recently serving as CEO of Cipla North America, a global pharmaceutical company based in Mumbai, India, from 2013 to 2017.

Previously, he worked for eight years at Teva Pharmaceuticals, where he served as senior vice president and Commercial Operating officer of the North American Generics division, the world's largest generic operation with multiple bns of dollars of annual sales.

Before that, he was Teva's vice president, Alliances and Business Development.

From 2001 to 2004, Crew was executive vice president, North America, for Dr. Reddy's Laboratories.

Crew began his pharmaceutical career at Bristol-Myers Squibb, where he held a number of senior management positions in global marketing, managed healthcare, marketing, business development and strategic planning.

Prior to his pharmaceutical roles, Crew served in the United States Army, where he rose to the rank of Captain.

Lannett, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.